Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 86,460

Document Document Title
WO/2018/220442A2
Provided herein are stromal stem cell therapeutics and methods of use in treating disease.  
WO/2018/219982A1
The present invention relates to pharmaceutical compositions comprising (E)-4-(2- (aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having chemical structure (I) or a pharmaceutically acceptable salt thereof as active pharmaceutical ...  
WO/2018/220237A1
The present invention relates to the use of grape skin or a composition comprising it as prebiotic for increasing the intestinal levels and/or activity of butyrate-producing bacteria, such as Faecalibacterium prausnitzii, F. prausnitzii ...  
WO/2018/221713A1
The purpose of the present invention is to solubilize a sparingly-soluble component in a solution, to provide a sparingly-soluble component-containing solution, to increase the solubility of a sparingly-soluble component in water (for ex...  
WO/2018/221521A1
The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives o...  
WO/2018/222947A1
A preparation comprised of one or more pellets having an outer shell and core. The outer shell is made of dissolvable material and said core containing poly (ethylene glycol).  
WO/2018/218344A1
A method for obtaining epithelial organoids is provided. In one embodiment, the method comprises culturing one or more epithelial ducts, epithelial duct fragments and/or epithelial stem cells isolated therefrom in contact with an extrace...  
WO/2018/219266A1
A composition for preparing hepatitis B vaccine, a preparation method therefor, and an application thereof. The composition comprises immune agonist activated ester, HBsAg and an aluminum adjuvant. On the basis of maintaining the hepatit...  
WO/2018/221543A1
The present invention provides: an I-type crystal of (E)-2-(7-trifluoromethyl chromane-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaph thalene-1-yl)acetamide having an excellent TRPV1 antagonistic activity; a medication and a medicat...  
WO/2018/221679A1
This 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative or a salt thereof has BRD4 inhibitory activity and is therefore useful as a drug, especially as an agent to prevent and/or treat diseases involving BRD4.  
WO/2018/222921A1
Presented herein are methods for treating bile acid diarrhea, short bowel syndrome (SBS), and cholecystectomy-associated diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficie...  
WO/2018/221562A1
According to the present invention, it is found that dopamine D2-like receptor agonists acts on a dopamine D2-like receptor in an activated Th cell and thereby inhibits the production of Interleukin-8 (IL-8).  
WO/2018/221447A1
Provided is a bone regeneration agent for regenerating bone that has been damaged or absorbed by inflammatory bone resorption disease, the agent containing a niacin compound as an active ingredient.  
WO/2018/222919A1
Presented herein are methods and compositions for treating congenital diarrheal disorders (CDD). Methods comprise administering to a patient in need thereof, an effective amount of a proanthocyanidin polymer composition from C. lechleri,...  
WO/2018/221627A1
A purslane processed material characterized by being obtained by adding yeast to a hot-water extract obtained by treating purslane by hot water, and culturing the yeast.  
WO/2018/219559A1
The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF╬...  
WO/2018/217638A1
Provided are methods for clinical treatment of a protein-losing enteropathy, such as lymphangiectasia, using an anti-C5 antibody, or antigen binding fragment thereof, in patients (e.g., pediatric patients).  
WO/2018/214699A1
Disclosed are an immune agonist and a composition thereof, and the use of same in the preparation of a hepatitis B vaccine and a preparation method for the composition. The composition has a stronger immune activation effect than the ori...  
WO/2018/215005A1
The yeast Kazachstania slooffiae, which is endemic in pig intestines, is used as an oral probiotic, prophylactic and/or therapeutic agent to improve intestinal health and gastrointestinal microbiota, especially in pigs.  
WO/2018/215960A1
A method and a composition comprising human milk oligosaccharides for decreasing the production of detrimental proteolytic metabolites such as ammonia and branched chain fatty acids in the intestinal microbiota of humans, which is useful...  
WO/2018/214395A1
Provided is a composition for improving intestinal microecology and preventing a chronic disease, comprising inulin, galacto-oligosaccharide, and a dietary fiber complex in a ratio of 1-75:1-75:5-95, preferably 10-50:10-50:25-50. Provide...  
WO/2018/215897A1
The present invention relates to a liquid mixture or solid mixture, in powder or granules, comprising or, alternatively, consisting of alginic acid and hyaluronic acid, or a salt thereof, for use in the treatment, in particular in the cu...  
WO/2018/217138A1
The invention relates to the chemistry of organic compounds, pharmacology and medicine and concerns therapies for obesity, psoriasis, Crohn's disease, colitis, irritable bowel syndrome, diarrhoea, nausea and vomiting, as well as a number...  
WO/2018/218211A1
Embodiments of the invention encompass identification and characterization of microbiota having potential or demonstrated therapeutic effects for certain conditions in certain non-human animals. In some embodiments, the identification an...  
WO/2018/217700A1
The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula (I), where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods ...  
WO/2018/217699A1
The invention relates to thiocarbamate prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula (I) wherein R1, R2, R3, R4 and n are as defined. The invention also relates to pharmaceutical compositions comprising...  
WO/2018/214736A1
Provided are a polyhydroxyphthalazinone compound, a preparation method therefor and the use thereof, wherein the general formula of the chemical structure of the polyhydroxyphthalazinone compound is as shown by formula (I). The polyhydro...  
WO/2018/213679A1
The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for trea...  
WO/2018/210259A1
Disclosed in the present invention is an application of an inhibitor capable of inhibiting the function of miR-183 in manufacture of medications used for increasing body weight, improving gastrointestinal function, and increasing subcuta...  
WO/2018/211413A1
The invention of the present application relates to crystalline forms of obeticholic acid and process for preparation thereof. Specifically, the invention of present application relates to crystalline forms VD1, VD2, VD3, VD4 and VD5 of ...  
WO/2018/209415A1
The present invention falls within the fields of pharmacy, medicine, chemistry and biotechnology. The compound of the present invention is a peptide and has shown surprising stability and ease of handling in comparison to the most simila...  
WO/2018/209639A1
Provided a lycine N-methyl transferase (GNMT) mutant gene which can prevent micro RNA has-miR-244 interference related to cancers, and which then can be used for preventing or treating liver diseases, the GNMT mutant gene being selected ...  
WO/2018/211323A1
Described herein are heterocyclic compounds, compositions, and methods for their use for treatment of disease.  
WO/2018/209601A1
The present invention relates to a pyrroloquinoline quinone derivative represented by formula I or a pharmaceutically acceptable salt thereof; U, V, W, X, Y and Z are each independently valued as an atom selected from among C, N, O, and ...  
WO/2018/212202A1
This disclosure provides methods for treating a hepatocellular carcinoma (e.g., unresectable HCC) with lenvatinib or a pharmaceutically acceptable salt thereof. Also encompassed by the disclosure are dosage regimens described herein of l...  
WO/2018/212361A1
The present invention provides a method of treating a disease associated with activated MYD88 signaling in a subject, including suppressing MYD88 expression in a subject by targeting an expression regulatory region of MYD88 gene by using...  
WO/2018/211742A1
A mask for activating the brain according to the present invention is characterized by being impregnated with an aqueous lemon grass extract which is extracted by an extraction method including the step of stirring lemon grass with stirr...  
WO/2018/211111A1
The present invention relates to novel dual amylin and calcitonin receptor agonists, specifically calcitonin-like amylinomimetic therapeutic agents, and extends to their use as medicaments in the treatment of various diseases and disorde...  
WO/2018/208847A1
The present invention relates to certain compounds of Formula la and pharmaceutical compositions thereof and their use in methods for the alleviation and/or treatment of pain arising from or related to inflammatory bowel disease, for exa...  
WO/2018/207852A1
The present invention provides a pharmaceutical composition comprising an iron chelator exhibiting antitumor activity, antibacterial activity and/or antivirus activity, and having reduced side effects. Specifically, the present invention...  
WO/2018/206711A1
The present invention provides an oligonucleotide comprising the sequence 5'-GGAACAGTTCGTCCATGGC-3' (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 150mg to 350mg ...  
WO/2018/205233A1
Disclosed is the use of an INGAP-PP peptide, an HIP peptide or an analogue thereof in the preparation of a drug for treating acute pancreatitis. The polypeptide compound can significantly reduce the increase in the levels of amylase and ...  
WO/2018/206027A1
It has been determined that the yeast Kazachstania slooffiae, which occurs endemically in hog-gut, is capable of utilising a plurality of L-amino acids, peptone, ammonium sulfate or urea as an individual N-source and in so doing, does no...  
WO/2018/208848A1
The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof and their use in methods for the alleviation and/or treatment of visceral pain, for example abdominal pain; pelvic pain; male pelvic...  
WO/2018/207110A1
The invention relates to a composition comprising one or more human milk oligosaccharides (HMOs) for use in stimulating the production of butyrate in the gastro-intestinal tract of a non-infant human and obtaining delayed increase in the...  
WO/2018/207882A1
Provided are compounds that can have an inhibitory action on BET family proteins and are expected to be useful as agents for the prevention or treatment of, for example, autoimmune diseases and/or inflammatory diseases (for example, rheu...  
WO/2018/209354A1
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), whic...  
WO/2018/206713A1
The present invention provides an oligonucleotide comprising the sequence 5'-GGAACAGTTCGTCCATGGC-3' (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 100mg to 150mg ...  
WO/2018/206722A1
The present invention provides an oligonucleotide comprising the sequence '-GGAACAGTTCGTCCATGGC-3' (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 100 mg to 350 mg...  
WO/2018/208369A1
Disclosed herein are therapeutic uses of polymer conjugates, including SNA-120 and SNA-125, comprising an active agent linked to a polymer, wherein the active agent comprises an indolocarbazole compound or derivative thereof. The disclos...  

Matches 1 - 50 out of 86,460